Search Results - "PETRAKOVA, KATARINA"

Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer by Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia V, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J. Thaddeus, Pivot, Xavier, Sondhi, Manu, Wang, Yingbo, Chakravartty, Arunava, Rodriguez-Lorenc, Karen, Taran, Tetiana, Jerusalem, Guy

“…An earlier report documented significant improvement in progression-free survival among patients with metastatic breast cancer treated with fulvestrant and a…”
Get full text

Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3 by Slamon, Dennis J, Neven, Patrick, Chia, Stephen, Fasching, Peter A, De Laurentiis, Michelino, Im, Seock-Ah, Petrakova, Katarina, Bianchi, Giulia Val, Esteva, Francisco J, Martín, Miguel, Nusch, Arnd, Sonke, Gabe S, De la Cruz-Merino, Luis, Beck, J Thaddeus, Pivot, Xavier, Vidam, Gena, Wang, Yingbo, Rodriguez Lorenc, Karen, Miller, Michelle, Taran, Tetiana, Jerusalem, Guy

“…Purpose This phase III study evaluated ribociclib plus fulvestrant in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative…”
Get full text

Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study by Cortes, Javier, MD, O'Shaughnessy, Joyce, MD, Loesch, David, MD, Blum, Joanne L, MD, Vahdat, Linda T, MD, Petrakova, Katarina, MD, Chollet, Philippe, MD, Manikas, Alexey, MD, Diéras, Veronique, MD, Delozier, Thierry, MD, Vladimirov, Vladimir, MD, Cardoso, Fatima, MD, Koh, Han, MD, Bougnoux, Philippe, MD, Dutcus, Corina E, MD, Seegobin, Seth, MSc, Mir, Denis, MSc, Meneses, Nicole, MSHS, Wanders, Jantien, MD, Twelves, Chris, Prof

“…Summary Background Treatments with survival benefit are greatly needed for women with heavily pretreated metastatic breast cancer. Eribulin mesilate is a…”
Get full text

Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial by Krop, Ian E, Dr, Mayer, Ingrid A, MD, Ganju, Vinod, FRACP, Dickler, Maura, MD, Johnston, Stephen, MD, Morales, Serafin, MD, Yardley, Denise A, MD, Melichar, Bohuslav, Prof, Forero-Torres, Andres, MD, Lee, Soo Chin, MRCP, de Boer, Richard, FRACP, Petrakova, Katarina, PhD, Vallentin, Susanne, MD, Perez, Edith A, MD, Piccart, Martine, Prof, Ellis, Matthew, Prof, Winer, Eric, Prof, Gendreau, Steven, PhD, Derynck, Mika, MD, Lackner, Mark, PhD, Levy, Gallia, MD, Qiu, Jiaheng, PhD, He, Jing, MD, Schmid, Peter, Prof

“…Summary Background Inhibition of phosphatidylinositol 3-kinase (PI3K) is a promising approach to overcome resistance to endocrine therapy in breast cancer…”
Get full text

Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients by DOBES, PETR, PODHOREC, JAN, COUFAL, OLDRICH, JURECKOVA, ANDREA, PETRAKOVA, KATARINA, VOJTESEK, BORIVOJ, HRSTKA, ROMAN

“…High rates of mutation in the TP53 tumor suppressor gene have been found in many human cancers, including breast tumors, making p53 one of the most studied…”
Get full text

Biomarker Dynamics and Long-Term Treatment Outcomes in Breast Cancer Patients with Residual Cancer Burden after Neoadjuvant Therapy by Holanek, Milos, Selingerova, Iveta, Fabian, Pavel, Coufal, Oldrich, Zapletal, Ondrej, Petrakova, Katarina, Kazda, Tomas, Hrstka, Roman, Poprach, Alexandr, Zvarikova, Maria, Bilek, Ondrej, Svoboda, Marek

“…A residual cancer burden after neoadjuvant therapy (NAT) for breast cancer (BC) is associated with worse treatment outcomes compared to patients who achieved…”
Get full text

Overall survival with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): A randomised, double-blind, placebo-controlled, phase 3 trial by Holmes, Frankie A., Moy, Beverly, Delaloge, Suzette, Chia, Stephen K.L., Ejlertsen, Bent, Mansi, Janine, Iwata, Hiroji, Gnant, Michael, Buyse, Marc, Barrios, Carlos H., Silovski, Tajana, Šeparović, Robert, Bashford, Anna, Zotano, Angel Guerrero, Denduluri, Neelima, Patt, Debra, Gokmen, Erhan, Gore, Ira, Smith, John W., Loibl, Sibylle, Masuda, Norikazu, Tomašević, Zorica, Petráková, Katarina, DiPrimeo, Daniel, Wong, Alvin, Martin, Miguel, Chan, Arlene

“…ExteNET showed that neratinib, an irreversible pan-HER tyrosine kinase inhibitor, given for 1 year after trastuzumab-based therapy significantly improved…”
Get full text

Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial by Mittendorf, Elizabeth A, Lu, Biao, Melisko, Michelle, Price Hiller, Julie, Bondarenko, Igor, Brunt, Adrian Murray, Sergii, Grybach, Petrakova, Katarina, Peoples, George E

“…In phase I/II studies, nelipepimut-S (NP-S) plus GM-CSF vaccine was well tolerated and effectively raised HER2-specific immunity in patients with breast…”
Get full text

First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study by Thomssen, Christoph, Pierga, Jean-Yves, Pritchard, Kathleen I, Biganzoli, Laura, Cortes-Funes, Hernan, Petráková, Katarína, Kaufman, Bella, Duenne, Anja, Smith, Ian

“…The prognosis for patients with triple-negative breast cancer (TNBC) is poor and treatment options are limited. Bevacizumab improves the efficacy of standard…”
Get more information

Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer by Hortobagyi, Gabriel N., Stemmer, Salomon M., Burris, Howard A., Yap, Yoon-Sim, Sonke, Gabe S., Hart, Lowell, Campone, Mario, Petrakova, Katarina, Winer, Eric P., Janni, Wolfgang, Conte, Pierfranco, Cameron, David A., André, Fabrice, Arteaga, Carlos L., Zarate, Juan P., Chakravartty, Arunava, Taran, Tetiana, Le Gac, Fabienne, Serra, Paolo, O’Shaughnessy, Joyce

“…The addition of ribociclib, a cyclin-dependent kinase inhibitor, to the aromatase inhibitor letrozole in women with metastatic hormone receptor–positive,…”
Get full text

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial by Chan, Arlene, Prof, Delaloge, Suzette, MD, Holmes, Frankie A, MD, Moy, Beverly, MD, Iwata, Hiroji, MD, Harvey, Vernon J, MD, Robert, Nicholas J, MD, Silovski, Tajana, MD, Gokmen, Erhan, MD, von Minckwitz, Gunter, Prof, Ejlertsen, Bent, MD, Chia, Stephen K L, MD, Mansi, Janine, MD, Barrios, Carlos H, Prof, Gnant, Michael, Prof, Buyse, Marc, ScD, Gore, Ira, MD, Smith, John, MD, Harker, Graydon, MD, Masuda, Norikazu, MD, Petrakova, Katarina, MD, Zotano, Angel Guerrero, MD, Iannotti, Nicholas, MD, Rodriguez, Gladys, MD, Tassone, Pierfrancesco, Prof, Wong, Alvin, PharmD, Bryce, Richard, MBChB, Ye, Yining, PhD, Yao, Bin, MS, Martin, Miguel, Prof

“…Summary Background Neratinib, an irreversible tyrosine-kinase inhibitor of HER1, HER2, and HER4, has clinical activity in patients with HER2-positive…”
Get full text

AMEERA-3: Randomized Phase II Study of Amcenestrant (Oral Selective Estrogen Receptor Degrader) Versus Standard Endocrine Monotherapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer by Tolaney, Sara M, Chan, Arlene, Petrakova, Katarina, Delaloge, Suzette, Campone, Mario, Iwata, Hiroji, Peddi, Parvin F, Kaufman, Peter A, De Kermadec, Elisabeth, Liu, Qianying, Cohen, Patrick, Paux, Gautier, Wang, Lei, Ternès, Nils, Boitier, Eric, Im, Seock-Ah

“…Amcenestrant (oral selective estrogen receptor degrader) demonstrated promising safety and efficacy in earlier clinical studies for endocrine-resistant,…”
Get full text

nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer by Hamilton, Erika, Cortes, Javier, Ozyilkan, Ozgur, Chen, Shin-Cheh, Petrakova, Katarina, Manikhas, Aleksey, Jerusalem, Guy, Hegg, Roberto, Huober, Jens, Zhang, Wei, Chen, Yanyun, Martin, Miguel

“…Purpose Resistance to endocrine therapy poses a major clinical challenge for patients with hormone receptor-positive (HR +), human epidermal growth factor…”
Get full text

Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2− advanced breast cancer in the randomized MONALEESA-2 trial by O’Shaughnessy, Joyce, Petrakova, Katarina, Sonke, Gabe S., Conte, Pierfranco, Arteaga, Carlos L., Cameron, David A., Hart, Lowell L., Villanueva, Cristian, Jakobsen, Erik, Beck, Joseph T., Lindquist, Deborah, Souami, Farida, Mondal, Shoubhik, Germa, Caroline, Hortobagyi, Gabriel N.

“…Purpose Determine the efficacy and safety of first-line ribociclib plus letrozole in patients with de novo advanced breast cancer. Methods Postmenopausal women…”
Get full text

Everolimus Plus Exemestane in Postmenopausal Patients with HR+ Breast Cancer: BOLERO-2 Final Progression-Free Survival Analysis by Yardley, Denise A., Noguchi, Shinzaburo, Pritchard, Kathleen I., Burris, Howard A., Baselga, José, Gnant, Michael, Hortobagyi, Gabriel N., Campone, Mario, Pistilli, Barbara, Piccart, Martine, Melichar, Bohuslav, Petrakova, Katarina, Arena, Francis P., Erdkamp, Frans, Harb, Wael A., Feng, Wentao, Cahana, Ayelet, Taran, Tetiana, Lebwohl, David, Rugo, Hope S.

“…Introduction Effective treatments for hormone-receptor-positive (HR + ) breast cancer (BC) following relapse/progression on nonsteroidal aromatase inhibitor…”
Get full text

Abstract OT2-11-02: Ameera-1 Arm 4: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with everolimus in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer by Campone, Mario, Neven, Patrick, Petrakova, Katarina, Braga, Sofia, Celanovic, Marina, Cohen, Patrick, Gosselin, Alice, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, Boni, Valentina

“…Abstract Background Amcenestrant (SAR439859) is an optimized oral SERD with potent dual activity that antagonizes and degrades the ER, resulting in inhibition…”
Get full text

Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer : The pre-operative arimidex compared to tamoxifen (PROACT) trial by CATALIOTTI, Luigi, BUZDAR, Aman U, NOGUCHI, Shinzaburo, BINES, Jose, TAKATSUKA, Yuichi, PETRAKOVA, Katarina, DUBE, Pierre, DE OLIVEIRA, Celia Tosello

“…The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter study comparing anastrozole with tamoxifen as a preoperative…”
Get full text

Abstract P1-18-11: Analysis of first-line (1L) patients (pts) with de novo disease vs late relapse and all pts with vs without prior chemotherapy (CT) in the MONALEESA-3 (ML-3) trial by De Laurentiis, Michelino, Lambertini, Matteo, Chia, Stephen, Rugo, Hope S, Petrakova, Katarina, Villanueva, Cristian, Hurvitz, Sara, Beck, J. Thaddeus, Lteif, Agnes, Haftchenary, Sina, Deore, Uday, Wu, Jiwen, El-Saghir, Nagi

“…Abstract Background: The phase 3 ML-3 trial demonstrated significant OS benefit for ribociclib (RIB) + fulvestrant (FUL) over placebo (PBO) + FUL as first- or…”
Get full text

Abstract P1-17-11: Updated data from AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), combined with palbociclib in postmenopausal women with ER+/HER2- advanced breast cancer by Chandarlapaty, Sarat, Linden, Hannah M, Neven, Patrick, Petrakova, Katarina, Bardia, Aditya, Kabos, Peter, Braga, Sofia, Boni, Valentina, Gosselin, Alice, Celanovic, Marina, Cohen, Patrick, Paux, Gautier, Pelekanou, Vasiliki, Ternès, Nils, Lee, Joon Sang, Campone, Mario

“…Abstract Background: In Arm 2 of the ongoing AMEERA-1 trial (NCT03284957), amcenestrant, an optimized oral SERD combined with the CDK4/6 inhibitor (CDK4/6i)…”
Get full text

Abstract OT2-11-04: Ameera-1 Arm 5: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with abemaciclib in postmenopausal women with ER+/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer by Campone, Mario, Chandarlapaty, Sarat, Bardia, Aditya, Neven, Patrick, Petrakova, Katarina, Kabos, Peter, Boni, Valentina, Braga, Sofia, Celanovic, Marina, Cohen, Patrick, Gosselin, Alice, Cartot-Cotton, Sylvaine, Pelekanou, Vasiliki, Linden, Hannah

“…Abstract Background Endocrine therapy in combination with a targeted cyclin-dependent kinase (CDK) 4/6 inhibitor is the clinical standard for treatment of…”
Get full text